Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Injectable Aesthetics
    • Dermatological Skincare
    • Therapeutic Dermatology
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2024
    • The aesthetic impact of medication-driven weight loss
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Podcasts
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • For society
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Home
  • Investors

EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology

Press release

Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum

Press release

Powered by Peptides: Galderma introduces Cetaphil Healthy Renew, a retinol alternative skincare range

Press release

Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement

Press release

Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology

Press release

Galderma raises approximately USD 1 billion for newly issued shares in a private placement round

Press release

Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4

Press release

WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology

Press release

Galderma receives FDA approval for its newest hyaluronic acid filler, Restylane® Eyelight™

Press release

Galderma receives FDA approval for Sculptra® for cheek wrinkles

Press release

Pagination

  • Previous page Previous Page
  • Next page Next Page
Subscribe to Press release
  1. Home
  2. Press release

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2025

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back